$LXRP Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments

$GGBXF Rapid Expansion into Malls for New Wave of Hemp-Derived Wellness Products

New York, NY – June 11, 2019 – Cannabis’ mainstream appeal continues to grow, Wall Street has taken notice of the marijuana industry’s potential for quintupling, at minimum, in worldwide cannabis sales through 2029. Much of the increase in appeal is coming through the availability of cannabidiol (CBD) products, namely in the retail space. Major retailers and retail property owners are opening their doors to selling hemp-derived products from companies including Green Growth Brands (CSE:GGB) (OTC:GGBXF), Green Thumb Industries Inc. (OTC:GTBIF) (CSE:GTII), iAnthus Capital Holdings, Inc. (OTC:ITHUF) (CSE:IAN), Curaleaf Holdings, Inc. (OTC:CURLF) (CSE:CURA) and MedMen Enterprises Inc. (OTC:MMNFF) (CSE:MMEN).

Leading the charge into malls across the United States is retail-oriented Green Growth Brands (CSE:GGB) (OTC:GGBXF) who just announced another major mall deal with prominent mall operator Brookfield Property Partners. Through the deal, the company’s Seventh Sense Botanical Therapy brand of CBD-infused products will be sold in GGB-owned stores starting with over 70 prime shop locations in Brookfield’s malls—and is in negotiations for additional stores to come.

The deal follows up a series of other mall and retail arrangements from Green Growth Brands and others, such as Tilray and iAnthus, including GGB’s previous deal with another mall magnate, Simon Property Group.

Key to mainstream acceptance is the surging popularity of CBD over its psychoactive cannabinoid cousin, THC. Since the green light to grow hemp was given late in 2018 with the approval of the US Farm Bill, expect more CBD-infused products to hit retail shelves everywhere.

As of late 2018, market research firm The Brightfield Group published a market overview and analysis on hemp-derived CBD. The report predicted the market would annually grow by 147%, from $591 million in 2018 to an estimated $22 billion by 2022.

Green Growth’s CBD products appear now in 10 Abercrombie & Fitch stores in Massachusetts, California, Colorado, and Nevada, and even more impressively in 96 US-based DSW stores—for a whopping 54,960 units.

Not to be outdone in terms of retail footprints, Curaleaf Holdings signed a deal with pharmacy giant, CVS to sell its own non-intoxicating hemp products in more than 800 CVS stores.

On the more ritzy side of the retail scene, Green Thumb Industries has broken through into the upper echelon through a deal made with Barneys New York. Through the acquisition of premium brand Beboe, Green Thumb products will be featured in the new locations for the Barneys version of a dispensary, titled “The High End”.

Perhaps cornering the mid-range market, are cannabis retail trendsetters MedMen Enterprises, who recently expanded their footprint in California. Dubbed the “Apple Store of pot”, MedMen retail locations are found in prominent locations in Los Angeles, Las Vegas, and New York.

The Rise of Marijuana in Malls

The bulk of Green Growth Brands (GGB-GGBXF) CEO Peter Horvath’s career successes have come inside of malls across the United States and around the world. The retail expert built a reputation while serving in C-level positions at several of the biggest names found in nearly every major mall—including with American Eagle Outfitters, Victoria’s Secret, Designer Brands and others.

Now with GGB, he’s parlaying his expertise both with the company’s main dispensary chain The+Source, and a chain of stores and kiosks for the Seventh Sense Botanical Therapy brand.

Previously in an interview with BNN Bloomberg, Horvath boldly stated, “There’ll be 100 million footsteps that will be exposed to CBD products by the end of the year.”

Already, the company has secured deals with two of the continent’s leading mall operators, Simon Property Group Inc. and more recently with Brookfield Property Partners.

“Brookfield Properties operates some of the most exciting and visited malls in the country, and we are thrilled to introduce our CBD shops to their centers,” said Peter Horvath, CEO of Green Growth Brands. “We know that consumers prefer to buy personal care and beauty products from physical stores, and this partnership will allow us access to millions of consumers.”

The benefits are mutual for both parties. Green Growth Brands gains access to the properties of one of the world’s largest investors in real estate. Brookfield, in turn, gains a growing brand, run by a team of experts familiar with mall spaces and how to best capitalize on foot traffic.

“Curation of our shopping centers is fundamental to our ongoing evolution,” said Sandeep Mathrani, CEO of Brookfield Properties’ retail group and Vice Chairman of Brookfield Property Group. “It is our job to bring in retail offerings and experiences that today’s consumer desires and this includes GGB’s CBD products. GGB is at the forefront of this trend and we are pleased they will expand their reach within our portfolio.”

Along with the rollout of shops under the Seventh Sense Botanical Therapy brand, GGB is also introducing its new prestige brand, Green Lily and 4 locations will open in the near future at Brookfield shopping centers.

The launches coincide with a deal with another mall giant, Simon Property Group. The strategy is to open brand-specific kiosks and stores in malls across the USA. The kiosk/store rollout will take place in 95 shopping malls, in 108 locations, and will offer approximately 40 different CBD-infused topical beauty products that will sell for between US$19-$29 per item.

Beyond just Brookfield and SPG, GGB products will be found in other malls as well, through both Abercrombie & Fitch and Designer Brands stores. These products will include body scrubs, bath bombs, cleansing oils, lotions and lip balms.

By 2020, the company aims to open 450 CBD-focused kiosks in prime mall locations within high-traffic, desirable sections of each mall. Through this strategy, the company projects a 2021 revenue of $120 million across 450 mall kiosks with EBITDA of 32%—an EBITDA per kiosk of $86,400.

Other Players Driving the CBD Retail Revolution

After getting its foot in the door in the new “High End” stores from Barneys New York, Green Thumb Industries Inc. (OTCQX:GTBIF) (CSE:GTII) has moved forward on its own Rise-branded locations. Having recently launched its 20^th Rise store (its third in Florida), there’s no official word yet on whether or not the Beboe line of CBD-infused skincare products will be available in all of the companies locations and distribution points in Illinois, Maryland, California, Pennsylvania, and Nevada.

Soon after a $14M acquisition in March, iAnthus Capital Holdings, Inc. (OTCQX:ITHUF) (CSE:IAN)  took over CBD For Life, a national brand of CBD products. Shortly after the deal was completed, they completed a deal with Urban Outfitters to sell CBD For Life in tow of its California stores and four of its New York store.

Also in March, Curaleaf Holdings, Inc. (OTCQX:CURLF) (CSE:CURA) announced a deal with CVS Health to sell its lotions and transdermal patches in 10 states, and more than 800 stores. The company is also looking to break into the lucrative pet supply market, with the launch of Bido, hemp-based CBD products for pets.

Perhaps the most unique CBD product being sold is CBD-infused PMS suppositories from Foria. Unlike the many topical CBD-infused menstrual pain-relief creams on the market, these items deliver 60mg of THC and 10mg of CBD in a way that more effectively targets inflammation closer to the source, and are sold for $20 a piece at the MedMen Enterprises Inc. (OTCQX:MMNFF) (CSE:MMEN) location in West Hollywood. MedMen also offers a wide range of CBD products to its customers, including pain creams, gummies, drops, mints, sprays, and vape pens.

For a free research report on Green Growth Brands (CSE: GGB) (OTCPK:GGBXF), visit potstocknews.com.

Potstocknews.com (PSN) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with PSN or any company mentioned herein. The commentary, views and opinions expressed in this release by PSN are solely those of PSN and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable PSN and FNM for any investment decisions by their readers or subscribers. PSN and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (PSN), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (PSN) has not independently verified or otherwise investigated all such information. None of the Author, PSN, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty six hundred dollars by PSN, a non-affiliated third party to distribute this commentary on behalf of Green Growth Brands

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PSN and FNM undertake no obligation to update such statements.

Media Contact:

FN Media Group, LLC

info@financialnewsmedia.com

+1(561)325-8757

$NETE 420 with CNW – Rhode Island Invites Blockchain Tech to Help Track Medical Marijuana

$INMB Featured in Exclusive NetworkNewsWire Broadcast

NEW YORK, June 11, 2019 — via NetworkNewsAudio – INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.

The interview can be heard at http://nnw.fm/94zqW.

Two of the co-founders of INmune Bio – CEO Dr. RJ Tesi, M.D. and CFO David Moss – join NNW host Stuart Smith for a discussion on the company’s novel approach to treating unsolved problems in cancer therapy and neurogenerative diseases such as Alzheimer’s.

“INmune Bio is a clinical stage biotech company, what does that mean? It means we are developing drugs to treat diseases that don’t have very good treatments,” Tesi says, also noting the company’s unique stance approach.

“It’s very unusual for a company to be focused on both cancer and neurodegenerative diseases such as Alzheimer’s, but that’s because we view Alzheimer’s disease as an immunologic disease,” he explains. “At least a third, probably closer to 50% of patients with Alzheimer’s Disease and dementia have chronic inflammation as an underlying cause of their cognitive decline. You need to manipulate the immune system to solve that problem and as an immunology company, we do that.”

INmune Bio differentiates itself from other immunology companies by focusing on the innate immune system while the majority conduct research on the adaptive immune system or T cells. The company’s clinical research and drug candidate pipeline centers on three promising approaches to treating diseases related to the innate immune system.

“Humans have two immune systems, the adaptive and the innate immune system, and they work together in this very elegant system,” Tesi says. “We’ve got all these great therapies to treat the adaptive immune system, diseases that relate to T cells, but we don’t have much to treat those diseases related to the innate immune system.”

INmune Bio’s INKmune™ biologic delivery system works by priming natural killer (NK) cells to attack hidden, residual cancer cells. The company’s INB03 checkpoint inhibitor targets myeloid derived suppressor cells which prevent a patient’s own immune system from attacking cancer cells. Also in the company’s pipeline is XPro1595, which targets the microglial immune cells of the brain that are a cause of neuroinflammation which can kill nerve cells and promote synaptic dysfunction or dementia in Alzheimer’s disease patients. A $1 million “Part the Cloud” grant awarded by the Alzheimer’s Association helps fund INmune Bio’s XPro1595 research program.

From an operational standpoint, 2019 has been a year of “firsts” for INmune Bio as the company went public and commenced trading on the NASDAQ. Additionally, subsequent financings and the Alzheimer’s Association grant provided funding to pursue further research on the company’s three drug candidates with ongoing phase I clinical trials generating data and upcoming phase II clinical trials in the planning stages.

About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$GGBXF Continues Rapid Expansion with Plans to Open Over 70 New Locations

COLUMBUS, OH, June 10, 2019 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) announced today an arrangement through which the Company will open over 70 prime shop locations with potential for more at Brookfield Properties’ shopping centers throughout the United States. These exciting plans will further expand GGB’s physical footprint to approximately 280 total locations by the end of 2019.

“Brookfield Properties operates some of the most exciting and visited malls in the country, and we are thrilled to introduce our CBD shops to their centers,” said Peter Horvath, CEO of Green Growth Brands. “We know that consumers prefer to buy personal care and beauty products from physical stores, and this partnership will allow us access to millions of consumers.”

With a portfolio of over 160 best-in-class retail real estate assets, Brookfield Properties’ retail properties are hubs for communities across the U.S., featuring shopping, dining, entertainment and gathering. Currently, there are seven GGB shops within the Brookfield Properties’ portfolio.

“Curation of our shopping centers is fundamental to our ongoing evolution,” said Sandeep Mathrani, CEO of Brookfield Properties’ retail group and Vice Chairman of Brookfield Property Group. “It is our job to bring in retail offerings and experiences that today’s consumer desires and this includes GGB’s CBD products. GGB is at the forefront of this trend and we are pleased they will expand their reach within our portfolio.”

In addition to Seventh Sense Shops, GGB is further expanding its chain of CBD-infused personal care product shops with a new prestige brand called Green Lily. Green Lily is a mindful-luxe CBD brand dedicated to empowering women.  Four Green Lily locations will open in the near-future at Brookfield Properties’ shopping centers.

All Green Growth Brands CBD products are sourced from U.S.-based, licensed hemp processors and are Farm Bill 2018 compliant. All products are rigorously tested and compliant with applicable requirements under the U.S. FDA, Health Canada, and EU Cosmetic Regulations, as well as the California Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65). GGB sells and distributes topical CBD products only in jurisdictions that permit such sale.

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, Meri + Jayne, and has a licensing agreement with the Greg Norman Brand. Already boasting the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. Learn more about our vision at GreenGrowthBrands.com.

About Seventh Sense Botanical Therapy
Seventh Sense Botanical Therapy creates CBD-infused botanical body care using the finest ingredients on earth. Crafted with wellness in mind, Seventh Sense aims to make CBD an accessible part of self-care routines across the country. Discover the magic of CBD at shops across the country and online at ShopSeventhSense.com.

About Brookfield Properties
Brookfield Properties is a fully-integrated, global real estate services company, providing industry-leading portfolio management capabilities across the real estate investment strategies of Brookfield Asset Management — a global alternative asset manager with over $365 billion in AUM.

Brookfield Properties develops and manages premier real estate with a focus on maximizing the tenant experience in addition to the investment and operational performance of the asset. We also focus on integrating leading-edge real estate technologies which enables us to be at the forefront of innovation and sustainability – benefiting not only our tenants and business partners, but also the communities in which we operate. For more information about our approach to operating and developing best-in-class real estate, please visit brookfieldproperties.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies, including with respect to its retail shop strategy; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including without limitation, the expansion of GGB’s Seventh Sense brand, the expected access to new customers in premier retail locations and the expected opening date of the first GGB shop, is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act“), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

$TGODF $TGOD NBA Commissioner Says the League’s Cannabis Rules Could Be Updated

$YGYI set to join Russell 3000 Index

SAN DIEGO, June 10, 2019  — Youngevity International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company, today announced that the Company is set to join the broad-market Russell 3000^® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000^® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Steve Wallach, Chairman and CEO of Youngevity, stated, “We are proud to be included in the Russell 3000 index and look forward to greater exposure to institutional investors as we move up from the Russell Micro Cap index to the Russell 3000.  This represents another important milestone for the company since we became listed on the Nasdaq exchange in June of 2017.”

“We are pleased to be added to the Russell 3000 Index and the other appropriate indexes that will come as a result of our inclusion,” said Dave Briskie, President and CFO of Youngevity International, Inc.  “According to Nasdaq, over the last 90 days, YGYI has added 12 new Institutional Investors and Institutional share ownership in YGYI has increased by 543,000 shares.  We believe our inclusion will continue this trend and broaden our group of institutional investors.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000^® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Youngevity International, Inc
Youngevity International, Inc. (NASDAQ: YGYI), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise.  The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter.

About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and includes statements regarding the additional exposure that we anticipate from the our inclusion on the Russell 3000 and our inclusion continuing to broaden our group of institutional investors. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to increase our exposure and continue to expand our institutional ownership as a result of our inclusion on the Russell 3000,  our ability to strategically position ourselves within the CBD space, our ability to continue our coffee segment growth, our ability to continue our international growth, our ability to leverage our platform and global infrastructure to drive organic growth, our ability to improve our profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution,  our ability to continue our financial performance and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

$OGI Canadian Cannabis Licensed Producers See Benefits of Big Board U.S. Listings

New York, NY – June 10, 2019 – Another Canadian licensed pot producer just entered the fray on a major U.S. exchange, as OrganiGram Holdings Inc. (NASDAQ:OGI) (TSX-V:OGI) began trading on the Nasdaq. Opening at a price of approximately $8, the under-the-radar LP joined the ranks of other large Canadian players getting uplisted to a U.S big board.

When it first announced the uplisting back in late April, OrganiGram Holdings Inc. stock was trading near $6.50—having more than doubled the low prices witnessed back in December. Now the LP has joined Tilray Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Village Farms International, Inc. (NASDAQ:VFF) (TSX:VFF), and recently-IPO’d Greenlane Holdings, Inc. (NASDAQ:GNLN), on the NASDAQ, and looking to reap the benefits of such exposure.

With a market cap of approximately $1.3 billion, OrganiGram Holdings Inc. (NASDAQ:OGI) (TSX.V:OGI) won’t be the largest or smallest LP stock by market capitalization on the Nasdaq—that would be Cronos (~ $5.423 billion^[1]) and Village Farms (~$652.265 million^[2]).

While some of the larger players have struggled to increase their valuations on big boards such as the Nasdaq and the NYSE, the mid-tier players have seen more successes.

Take, for instance, Village Farms International, Inc. which was the most recent Canadian LP to receive an uplisting to the Nasdaq back on February 21, 2019. Starting at a price of $9.85 on its first day, Village Farms saw its stock hit a high $17.45 exactly one month later, and now trades at more than 33% higher than it did on day one.^[3]

Both Tilray Inc. and Greenlane Holdings, Inc. IPO’d on the Nasdaq, whereas Cronos, Village Farms, and now OrganiGram, went through the uplisting process from the OTC board.

Listing on a major U.S exchange typically helps a company due to improved visibility, validity, and liquidity. Typically trading volume picks up significantly, the bid-ask spread tightens, and potentially the volatility often associated with OTC-listed pot stocks can decrease.

OrganiGram Holdings Inc. (OGI) becomes the latest to receive approval from the same exchange that has companies like Apple Inc., Microsoft Corporation and Tesla, Inc. among others.

Already, the stock has seen a noticeable increase in volume, trading no lower than 2 million shares per day since the two days in the lead-up to the uplisting.^[4] In comparison, the only other time the stock traded more than 2 million or more shares in one day in 2019 was April 30^th—the day after the Nasdaq announcement was made.^[5]

Nasdaq Approval Driving Further Evidence of Momentum

Prior to its approval, OrganiGram Holdings Inc. (OGI) had already made a very strong case for investors. Posting very strong Q2 2019 results recently for the quarter ended February 28^th, the LP posted revenues of C$26.9 million that doubled the prior quarter^[6].

OrganiGram is one of only four companies with distribution arrangements in all 10 Canadian provinces—a distinction only heavyweights Canopy Growth Corp., CannTrust and Aphria also share.

During Q2 2019, OrganiGram generated an impressive adjusted gross margin* of C$16 million or 60% and adjusted EBITDA*  of C$13.3 million for a margin of 49%. It was able to keep its cultivation costs per gram under $1—at a low cash cost of C0.65/gram*, and all-in cost of C$0.85/gram of dried flower harvested, both of which are the lowest among Canadian publicly reporting LPs.^[7]

It has largely achieved this through the implementation of state of the art technology and proprietary software that has helped increase yields. In particular, OrganiGram has a 3-tier indoor cultivation technology, effectively maximizing the facility’s available cultivation space, and controlling critical facets of the growing environment (light, temperature, humidity) contributing to lower growing costs and higher margins.

Gaining a boost from the Nasdaq filing is one thing, but OrganiGram also has a track record of meeting its targets which reflects s its focus on execution and driving shareholder value.

The company is on track to complete construction of its Phase 4 expansion for target annual production capacity of 113,000 kilograms* by its target date –  the end of 2019^[8].  In addition to the expansion, OrganiGram Holdings Inc. (NASDAQ:OGI) (TSX.V:OGI) is also refurbishing 56,000 square feet for its own edibles facilitys and additional extraction capacity in preparation for the Canadian legalization of edibles and derivative products, expected this fall. As the company readies itself to demonstrate a leadership position in this new edibles and derivatives market, it  announced a C$15 million investment commitment in a high-speed, high-capacity, fully-automated production line with the ability to produce an estimated 4 million kilograms of exceptional chocolate cannabis edibles per year. Organigram expects to take delivery of the line in the fall.^[9]

The company is further diversifying its portfolio with innovative partnerships in a bid to uphold its commitment to a leadership position with next-generation cannabis products. OrganiGram Holdings Inc. (OGI) has been selected as one of the four Canadian launch partners of PAX Era, the premium oil vaporizer created by PAX Labs, Inc., a leading consumer technology brand in the design and development of premium vapes for dry flower and concentrates.^[10] Organigram plans to offer Edison Cannabis Co. brand PAX Era pods coast to coast in Canada through its distribution arrangements in all 10 provinces.

These announcements are just the beginning of Organigram’s strategy to capture the next growth opportunity in the two largest segments of the edibles and derivative products market (based on US sales) with the company’s commitment to technology-driven innovation.  Estimates suggest vape pens alone currently represent the largest segment at approximately 25% of US sales based on form factor.^[11]

Additional LP Nasdaq Experiences

Nanaimo, BC-based Tilray Inc. (NASDAQ:TLRY) made a splash when it became the Nasdaq’s first pot IPO, back in July of 2018^[12]. Within the first three months of trading, the stock took off to its historic high in October 2018, topping $170 in its share price^[13]. The company has since come back down to earth but is still currently trading at more than 90% higher than its IPO price^[14].

The most recent Nasdaq IPO comes from Greenlane Holdings, Inc. (NASDAQ:GNLN), which is still just a bit more than a month old on the exchange.^[15] Still too new to assess on a long view, the honeymoon period has seemingly worn off, as its first day trading volume was over 7 million, whereas the company hasn’t traded more than 1 million in a day since May 6^th, and is trading at roughly 53% of its opening IPO price of $29^[16].

Toronto-based Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) was the first big splash on the Nasdaq from the sector, arriving on the scene in late February 2018^[17]. With its frequent 8-digit (sometimes 9-digit) trading volumes and over $5 billion market cap, Cronos is far and away from the largest LP by market cap on this exchange. Since trading on the Nasdaq, the company has gone from trading at $8.24 to a high of $21.92 almost exactly a year later^[18]. Currently, Cronos is trading above $15.50, at nearly a 90% increase since day one on the exchange^[19].

Since receiving its uplisting in February of this year^[20], Village Farms International, Inc. (NASDAQ:VFF) (TSX:VFF) has comfortably risen in value by roughly 33%. Within its first month on the exchange, the company hit its high of $17.45, before falling back to earth, rising back to $16 in April, and now settling in at its current $13.21 price point^[21]. Year-to-date, 2019 has been a remarkable story for Village Farms, which is now more than triple its open price on at the beginning of January 2019^[22]. The positive momentum of the company’s stock chart can be visibly seen beginning around the January 21, 2019 announcement of the application to get on the Nasdaq big board^[23].

$TGODF Expands Cultivation Operations Following Health Canada Authorization

$TCAN Closing of CDN$10 Million Brokered Private Placement of Units

Vancouver, British Columbia– TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) (OTC PINK: TCNAF) (“TransCanna” or the “Company”) is pleased to announce that it has closed its previously announced brokered private placement of units, generating aggregate gross proceeds of CDN$10,001,750.

An aggregate of 2,000,350 units of the Company (the “Units”) were sold at a price of CDN$5.00 per Unit (the “Offering”). The Offering was conducted by a syndicate of agents co-led by Haywood Securities Inc. and Canaccord Genuity Corp., and PI Financial Corp. (collectively the “Agents”).

Each Unit comprised one common share of the Company (each a “Share”) and one half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire an additional Share at a price of $6.00 until June 7, 2022. The Warrants are subject to an acceleration clause that would require their exercise within thirty days of notice from the Company in the event that the price of the Shares closes at or above $10.00 for a period of 20 consecutive trading days.

The Warrants are issued pursuant to a warrant indenture dated June 7, 2019 between the Company and its warrant agent, Odyssey Trust Company. A copy of the warrant indenture is available under the Company’s profile on SEDAR at www.sedar.com. The Company has agreed to seek a listing of the Warrants on the CSE at such time as all applicable resale restrictions have lapsed, subject to receipt of listing approval.

A commission of 7.0% of the gross proceeds of the Offering was paid through the payment of $700,122.50 in cash, as well as a corporate finance fee of $150,000, plus applicable taxes. In addition, the Agents received an aggregate of 140,024 transferable compensation options to acquire up to 140,024 Shares at a price of $5.00 per Share until June 7, 2022.

The Company intends to use the net proceeds of the Offering to fund further equipment purchases for its vertically integrated cannabis facility in Modesto, California, additional acquisitions, including the previously announced proposed acquisitions of Biovelle, Soldaze and Lyfted Farms and for working capital and general corporate purposes.

All securities issued pursuant to the Offering are subject to a four month hold period expiring October 8, 2019 in accordance with applicable Canadian securities laws.

In other news, the Company has engaged Umbrella Capital Group Ltd. to conduct market-making activities for the Company at a rate of thirty thousand dollars per month for a three month term. Umbrella Capital Group Ltd. is an independent financial services organization based in Toronto.

For further information, please visit the Company’s website at www.transcanna.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

Media Contact
TransCanna@talkshopmedia.com
604-738-2220

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (604) 609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to the proposed use of proceeds from the financing. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$PFSF Collaborates with Império for Commercial Marketing and Promotion of BOAPIN.com

$OGI Secures Partnership with PAX as Brand Partner

• Partnership with PAX builds on Organigram’s commitment to both quality and a strong leadership position with next generation cannabis products
• Organigram plans to offer Edison Cannabis Co. brand PAX Era pods coast to coast, through the Company’s distribution arrangements in all of Canada’s ten provinces
• Estimates suggest vape pens currently represent the largest segment of edibles and derivative based products at approximately 23 per cent of U.S. sales based on form factorⁱ

MONCTON, NB, June 7, 2019 – Organigram Holdings Inc. (NASDAQ: OGI) (TSXV: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis and extract-based products, is pleased to announce it has been selected as one of the four Canadian launch partners of PAX Era, the premium oil vaporizer created by PAX Labs, Inc., a leading consumer technology brand in the design and development of premium vaporizers for dry flower and concentrates, when concentrates become legal in Canada later this year.

Much like Organigram’s own Edison Cannabis Co. brand, the PAX portfolio features disruptive, industry-leading technology, on course to redefine the experience of vaping in Canada – and around the world.

“Cannabis 2.0 – the next generation of legal, adult use cannabis products – represents a world of opportunity,” says Greg Engel. “Innovative partnerships with exceptional companies like PAX mean our own product offering grows and our customers have access to cutting-edge technology and cannabis experiences.”

The agreement with PAX reflects Organigram’s own strategic commitment to growth and leadership through technology-driven innovation.

Organigram will produce and fill Edison Cannabis Company-branded pods specifically for the PAX Era platform. The pods will be filled onsite at Organigram’s Moncton facility at the Company’s Phase 5 refurbishment.

Organigram plans to work with and offer Edison Cannabis Co.-branded PAX Era pods to all 10 of its provincial partners to achieve coast to coast distribution. All sales and distribution will be subject to and in accordance with legislation related to extractable products in Canada.

Organigram has strategically been building up significant levels of concentrate in anticipation of the Cannabis 2.0 vape pens and edibles launch later in the 2019 calendar year.

“This is just the beginning,” says Engel. “Our team is constantly applying our best creative, consumer-focused thinking to developing exceptional, imaginative products that support our business objectives and delight our customers.”

About PAX Labs, Inc.

PAX is a leader in the design and development of premium app-controlled vaporization technologies and devices, for cannabis flower and concentrates. Headquartered in San Francisco, PAX has revolutionized the consumer experience through innovation and product design, and is committed to taking the guesswork out of cannabis with products that offer quality, transparency and predictability. PAX has sold more than 500,000 Era devices for oil concentrates and over one million devices in the flower vaporizer category. PAX is committed to its mission: establishing cannabis as a force for good. For more information, please visit ca.pax.com.

PAX Labs does not manufacture, produce or sell cannabis.

About Organigram Holdings Inc. 

Organigram Holdings Inc. is a NASDAQ Global Select and TSX Venture Exchange-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Co., Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such statements include statements with respect to the size of the edibles and derivatives market, ability to achieve adoption by the Company’s provincial partners, total expected market size based on estimates from U.S. experience, Organigram’s expected market position, consumer demand for products, timing for launch of product lines and brands and timing for implementation and effectiveness of the legal framework applicable to such product lines. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks associated with new product categories, extrapolation from U.S. experience being representative of Canadian market size, provincial receptiveness to new product categories, delays in regulation and timing for implementation, and such risks as disclosed in the Company’s most recent annual information form and other Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. We seek safe harbor.

$VVCIF Reports 2019 AGM Results

$LXRP DehydraTECH Delivers 475% More CBD to the Bloodstream

• LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes
• Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading volumes
• A DehydraTECH formulation achieved a 319 percent higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH delivery technology has demonstrated in animal lab tests that it can deliver cannabinoids to the bloodstream more quickly than conventional cannabinoid formulations (http://nnw.fm/fsKW4). At 15 minutes into the test, the DehydraTECH formulation achieved a blood concentration level that was 475 percent higher than a generic coconut oil formulation; at 60 minutes, the blood concentration level was 319 percent higher.

Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GGBXF CBD Beauty Is Blossoming, Say Analysts at Jefferies

Palm Beach, FL – June 6, 2019 – According to a recent industry article published this year, Jefferies analysts, after initiating coverage on the cannabis markets, followed up with additional coverage specific to the CBD industry and in particular CBD beauty products.  The article suggests Jefferies believes the CBD beauty market could reach $25 Billion globally in the next 10 years and could even amass 15 percent of the total skincare market.  The incredible potential of the CBD beauty market is thought to be enormous, given the possibility that many products could be sold over the counter and without the need for a prescription, clearly allowing consumers access to the products easily. CBD beauty products have quickly become all the rage now that industry analysts estimate it could be an entirely separate category from both recreational and medical marijuana. That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF),  Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF), Aleafia Health (TSX-V:ALEF) (OTC:ALEAF), Curaleaf Holdings Inc. (CSE:CURA) (OTC:CURLF), and Westleaf Inc. (TSX-V:WL) (OTC:WSLFF).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that will be launching Urban Juve CBD Skin Essentials—a new line of full-spectrum CBD-infused skin care products, in the fall. The new line will be made with certified organic, full-spectrum CBD distillate and Urban Juve’s proprietary hemp root oil to maximize skin renewal.  “We know that skin care brands need to stand out in a crowded marketplace, and Urban Juve does just that,” says Thomas Bond, Director of Yield Growth, and former COO of MAC Cosmetics. “The formulations are beautiful, and with the addition of CBD, we’re meeting the massive demand from wellness-minded consumers.”

“We are seeing an incredible demand for CBD skin care products in the marketplace—from a wide range of customers. We’re poised to make significant inroads in this space because we had the foresight to formulate CBD-compatible products from the beginning. Currently, we are working on a catalogue of more than 200 formulations,” says Sandi Lesueur, President of Urban Juve. “We also have the right team in place. We have experience achieving massive growth for international cosmetics companies, so we are well-positioned to be a major force in the CBD skin care market.”  Read the full Press Release and more for BOSS at:  https://www.financialnewsmedia.com/news-boss

Other cannabis-related developments from around the markets include:

Green Growth Brands Inc. (CSE:GGB)(OTCQB:GGBXF) announced that on Monday, June 3, 2019, it executed an arm’s length definitive agreement to acquire all of the issued and outstanding shares of capital stock of Spring Oaks Greenhouses, Inc. Spring Oaks holds a medical marijuana dispensary license and authorization to operate as a Medical Marijuana Treatment Center in the state of Florida. The medical marijuana dispensary license, received in April of this year, authorizes Spring Oaks to initiate production, processing, and dispensing of medical marijuana and marijuana products. The license grants the right, but not the obligation, to open up to 35 dispensaries, subject to an increase to 40 when the Florida Medical Marijuana program surpasses 300,000 patients.

“Entering Florida through the Spring Oaks acquisition will be a great addition to our existing MSO presence in Nevadaand Massachusetts, as well as to our CBD business that already has a national presence,” said Green Growth Brands CEO, Peter Horvath. “We admire several of the existing operators in the state and Florida is a special market, with favorable financials implications for the best operators. We look forward to quickly scaling our operations in the state and bringing our expertise to every patient.”

Aleafia Health (TSX-V:ALEF)(OTCQX:ALEAF) has completed the largest adult-use cannabis order in the Company’s history.  The Order is scheduled to depart from the Company’s facility today, with delivery to a Canadian provincial government for distribution to online and retail consumers. It will contain the Company’s branded Symbl oils, oral sprays and dried flower products. “We are extremely pleased to report the largest ever cannabis sale in our Company’s history,” said Aleafia Health CEO Geoffrey Benic. “Furthermore, with our Niagara Greenhouse and Outdoor Grow expansion in a plant-ready state, the assets are now in place to scale our cannabis health and wellness vision exponentially and build on today’s results.”

Curaleaf Holdings Inc. (CSE:CURA)(OTCQX:CURLF) announced its management will participate in the following institutional investor conferences in June 2019, including Eight Capital & Cassels Brock hosted State of the Union: American Cannabis Forum to be held in Toronto on Tuesday, June 4; Piper Jaffray’s Annual Consumer Marketplace Conference in New York City on Thursday, June 6; Canaccord Cannabis 100 CEO Summit in Half Moon Bay on Tuesday, June 11; Stifel Nicolaus 2019 Cross Sector Insight Conference to be held in Boston from Monday to Wednesday, June 10 – 12; and Oppenheimer’s Annual Consumer Growth & E-Commerce Conference to be held in Boston Tuesday and Wednesday, June 18 and 19.

Westleaf Inc. (TSX-V:WL) (OTCQB:WSLFF) just announced that its subsidiary, Westleaf Labs LP, has entered into a definitive agreement with a subsidiary of Xabis Inc., whereunder Xabis will provide technical expertise to the Company’s Calgary-based extraction, processing and manufacturing facility, which is on schedule to complete construction this month. The agreement will provide Westleaf with exclusive access to Xabis’s extraction, processing, manufacturing and product development expertise in the Canadian market. “This partnership is another part of the execution on Westleaf’s strategy of becoming a significant vertically integrated player in the Canadian cannabis industry,” said Scott Hurd, President and CEO of Westleaf. “We believe a diversified offering of derivative cannabis products will account for a major shift in consumer demand once legal. We are positioning to formulate unique, high quality cannabis derivative products and have partnered with an industry leader to complement our expertise in building and running these types of facilities. We are also excited to start offering contract manufacturing services to third parties.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated forty six hundred dollars for news coverage of the current press release issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$PFSF Agreement to Use BOAPIN.com Trade Portal for China/Brazil Transactions

TORONTO, June 06, 2019 — via NetworkWire – Pacific Software Inc. (OTC: PFSF) (“Pacific Software” or the “Company”) today announces that it has entered into a Memorandum of Understanding (MOU) with Império Assessoria em Informaçoes LTDA (Império) located in Sao Paulo, Brazil. Pursuant to the MOU, the parties agree to commercially market and promote the activities of the commodities trade portal BOAPIN.com powered by Pacific Software and Atlas Cargo Suite, an agribusiness, logistics management software module owned and operated by Império.

The MOU and further collaboration between the parties were created in an effort to increase trade between China and Brazil in sectors highly reliant on supply chain transparency, management and efficiency for commodities and products sold. Trade between the two countries is underdeveloped and technology solutions are expected to fuel growth in cross-border transactions and business expansion.

BOAPIN.com is uniquely positioned to supply competitive B2B pricing advantages to commodities traders by deploying cutting-edge technologies to its subscribers such as: trading data analytics, search/match interface, smart contracts, artificial intelligence (AI) and blockchain solutions. Given the current economic and trade environment, China is seeking additional commodities trading partners to offset the trade tariffs imposed by the USA. As such, Brazil is a viable supplementary trading partner alternative.

“This collaboration will include the commercial marketing and promotion of the BOAPIN.com platform as a front-end e-commerce solution and the assimilation of ‘Chain Integration Intelligence,’ a client application from the Atlas Cargo Suite into the BOAPIN portal,” stated Peter Pizzino, president of Pacific Software. Design and deployment of future generations of the enterprise applications and solutions will also be released upon completion.”

The deployment of the applications, tools and user solutions through the BOAPIN.com platform may include features such as: financial technologies (fintech), export payments, customs clearance, logistics, taxation and product certification.  These and other business technologies may provide competitive advantages to portal subscribers in commodities trading activities and other merchant offerings. In addition, the Atlas Cargo module will link BOAPIN.com to 12 ports, 37 warehouses and five logistics purveyors in Brazil.

About Pacific Software
Pacific Software Inc. (OTC: PFSF) is an enterprise designer, developer, licensor and operator of transactional solutions for most industries. It is postured for investments, mergers, acquisitions and business combination strategies for emerging technologies and digital platforms. The company recently launched and operates the BOAPIN.com portal, a versatile Application Service Provider (ASP) and commodities trading platform designed for international clients, traders and subscribers globally. For more information visit www.PacificSoftwareInc.com

About BOAPIN
BOAPIN.com is a multi-lingual and multi-faceted commodities trading portal uniquely positioned to deliver competitive B2B trading solutions to subscribers for the import/export trade sector. It may feature and deploy cutting-edge technologies such as Artificial Intelligence (AI), trading data analytics, smart contracts, and blockchain solutions utilizing IBM’s Backend as a Service (BaaS) infrastructure.  The BOAPIN platform aims to shorten trade cycles, increase trade efficiencies and increase global trade. Designed as an open architecture platform, BOAPIN would build an ecosystem which digitizes the trade process including; product listing, search/ marketing interface, finance, advertising, buyer /seller communications, product certification, logistics, trade, payment solutions, sales and order management.  For additional information please visit www.BOAPIN.com

About Império
The company designs and markets a diverse suite of agribusiness software modules specializing in logistics management, traceability and transparency for product delivery and shipment globally. Its Atlas Cargo Suite is a robust and automated user solution for product warehousing and/or shipment management in road, rail and waterways environments complete with monitoring of product movement, designed to avoid fraud and cargo misuse. The Atlas Cargo Suite is structurally developed for modular integrations with several types of peripherals including; road, rail or flow scales, gates, electronic sensors and PLCs. In 2018, Império processed 35 million tons of cargo including; 17.2 million tons of soy, 6.9 million tons of corn, multiple tons of sugar and 30% of the fertilizer market for Brazil. For additional information please visit www.imperio.com.br.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Pacific Software and are difficult to predict. Examples of such risks and uncertainties include but are not limited to whether the hyperledger blockchain technology solutions will be well received or utilized. Additional examples of such risks and uncertainties include, but are not limited to (i) Pacific Software’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Pacific Software’s ability to maintain existing, and secure additional, contracts with users of its solutions; (iii) Pacific Software’s ability to successfully expand in existing markets and enter new markets; (iv) Pacific Software’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Pacific Software’s business; (viii) changes in government licensing and regulation that may adversely affect Pacific Software’s business; (ix) the risk that changes in consumer behavior could adversely affect Pacific Software’s business; (x) Pacific Software’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent quarterly report on filed by Pacific Software with the Securities and Exchange Commission. Pacific Software anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Pacific Software assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contact:
Pacific Software Inc.
Info@PacificSoftwareInc.com
+1 844 513 0056

$NETE Rhode Island Invites Blockchain Tech to Help Track Medical Marijuana

$TCAN to Acquire Soldaze Cannabis Snacks: Video

• TransCanna Holdings has signed an LOI to acquire Soldaze cannabis-infused fruit snacks, one of its 15 planned premium cannabis brands
• TransCanna’s recently acquired 196,000-square-foot self-contained production and distribution facility in Modesto, California, was featured in a new video tour of the site
• The facility is being developed as a hub for statewide distribution to various company satellite facilities in premium markets
• The company has plans for developing a still-larger cultivation facility on the 5.5-acre Modesto site as it grows and obtains more funding

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) has signed a non-binding letter of intent, dated May 15, to acquire the branding asset package Soldaze from Santa Cruz, California-based Tres Ojos Naturals LLC. The move is part of TransCanna’s plan to put 15 premium cannabis brands on store shelves in the next 24 months, utilizing the company’s new 196,000-square-foot California facility as the hub for its operations. SolDaze produces cannabis-infused fruit snacks in California.

“Having reviewed over 100 branded products in California, we’ve been extremely selective in our acquisition vetting process,” TransCanna CEO Jim Pakulis stated in a news release about the…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://nnw.fm/TCAN

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$LXRP Expands Opportunities for 1906 Edibles

• LXRP has expanded its cannabis product relationship with Nuka Enterprises’ 1906 brand
• DehydraTECH enables 1906 chocolates to deliver on both function and flavor
• The company is expecting a tenfold increase in sales with expansion to legal markets

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), the developer and out-licenser for the disruptive and cost-effective DehydraTECH, recently announced that it has expanded its cannabis product relationship with Nuka Enterprises LLC, maker of 1906 cannabis edibles for high-functioning adults (http://nnw.fm/UzUV1).

Since its beginnings in 2016, 1906 chocolates have benefited from DehydraTECH technology. In three short years, Nuka has become Colorado’s fastest-growing edibles company, and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GNPX Developing Gene Therapy-based Approach to Treat Non-small Cell Lung Cancer

$TGODF Real Reasons CBD Products Are Projected To Outpace Marijuana

Palm Beach, FL – June 5, 2019 – Today, many marketers and retailers, seem to think that their brand(s) can become supercharged just by adding two words to their brand(s) name. More awareness. More sales.  Significantly increased revenues! All they have to do is to add the following: “CBD infused (insert the brand name here)”.  Beer, alcohol, candy, foods, lotions… pet food! Recent market reports, however, back up this phenomenon. Recent predictions for the CBD infused products market have created much enthusiasm and the optimists not only see the glass as half full… but they see it as overflowing! The predictions by the Brightfield Group, a well-respected industry reporting firm, in a much-quoted report said, in its headline: “ New Report Predicts CBD Market Will Hit $22 Billion by 2022 – Looking forward to relaxed hemp regulations, a new analysis estimates that the CBD market could explode — and outpace marijuana.” The company also said on its website that: “CBD is growing faster than cannabis in the U.S. and will soon be a $22 billion industry. It’s been flying under the radar but is set to explode…”   Active Companies from around the market with current developments this week include:  Leafbuyer Technologies, Inc. (OTC: LBUY), Sorrento Therapeutics, Inc. (NASDAQ: SRNE), PotNetwork Holdings, Inc. (OTC:POTN), The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON).

Brightfield also reported that retailers… big box retailers, are “Going after CBD.”   They continued:   “More and more retailers – including larger chains – are announcing both in-house products and partnerships with CBD brands… This is the tip of the iceberg. We expect large-scale entities to publicly enter the CBD market at a faster rate now that these big names have expressed serious interest, and because the potential market growth is staggering. In fact, we estimate that CBD beauty alone will hit nearly $290 million in 2019. This does not account for large sectors in the food, beverage, and pet industries.”

Leafbuyer Technologies, Inc. (OTCQB: LBUY) BREAKING NEWS:  Leafbuyer Technologies announced today a non-binding letter of intent to acquire majority stake in Las Vegas-based trade show operation CBD.io. CBD.io operates one of the largest and most visible expos in the CBD and vape industries.

The agreement additionally includes an ownership stake in an e-commerce website for wholesale and retail CBD products. Additional terms of the deal were not disclosed.

CBD is the common name for Cannabidiol, a prevalent, non-psychoactive cannabinoid found in cannabis. Preliminary research shows CBD may help relieve pain, anxiety, and other ailments.

“CBD has become a pop culture phenomenon, and trade shows are a lucrative and unsaturated sector of the industry,” said Kurt Rossner, CEO of Leafbuyer. “CBD.io is a profitable company and has a proven financial model that will increase Leafbuyer’s top line and be a powerful driver for earnings. The significant advantage of this acquisition is the ability for Leafbuyer to drive tremendous brand exposure to another fast-growing segment of the industry. Last year, CBD.io sold nearly 200 booths, this year we will cross sell our platform of over 400 clients and look to double that. We will be uniquely positioned to offer a true 360 solution to customers. Our product clients can access millions of consumers through digital and in-person methods to spread brand awareness and increase profits.”

The acquisition would double Leafbuyer’s current revenue run rate.

“In 2018, CBD.io hosted one of the largest and most successful hemp and CBD industry expos in the United States. We’re expanding this year to focus on more speakers and educational series, host nearly double the booths, and bring more value to our trade show clients,” said CBD.io CEO Robb Hackett. “CBD is a hot commodity in the United States, as well as other countries around the world. With Leafbuyer, we have our sights set on locations for trade show expansion in both Europe and Asia in 2020.”     Read this and more news for LBUY at:    https://www.financialnewsmedia.com/news-lbuy/  

In the industry developments and happenings in the market this week include:   

The Green Organic Dutchman Holdings Ltd. (OTCQX:TGODF) (TSX:TGOD) has secured a cannabis supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC), further expanding its footprint in Western Canada. AGLC, under the brand Alberta Cannabis, is Alberta’s legal, non-medical on-line cannabis store.

“Alberta is an important market for us as we continue to expand our distribution channels across Canada,” commented Brian Athaide, chief executive officer of the company. “With our production facilities in Hamilton, Ont., and Valleyfield, Que., coming on line in phases, we are thrilled to start distributing TGOD’s premium certified organic cannabis to AGLC.”

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) has entered into a multiyear supply agreement with Medipharm Labs Corp. Medipharm Labs will supply Cronos Group with approximately $30-million of high-quality private label cannabis concentrate over 18 months, and, subject to certain renewal and purchase options, potentially up to $60-million over 24 months. In addition, Cronos Group and Medipharm Labs have entered into a multiyear tolling agreement, where Cronos Group will supply bulk cannabis to Medipharm Labs’ state-of-the-art extraction facility in Barrie, Ont., to fulfill certain additional processing needs of the company.

“As the industry develops and matures, we see opportunity to work with companies like Medipharm Labs that provide specialized, high-quality services and inputs for our products,” said Mike Gorenstein, chief executive officer of Cronos Group. “Along with our internal capabilities, we are pleased to be working with Medipharm Labs to bring great products to consumers in anticipation of the derivative market launching in Canada this fall.”

PotNetwork Holdings, Inc. (OTCPK:POTN) announced this week that the Company’s online store generated over $1.1 million in exclusive web-based sales in May 2019. Compared with May 2018, in which online sales totaled $569,671, May 2019’s record online revenues represent a year-over-year increase of over 90%.

Diamond CBD’s online sales reflect a continual impressive growth of the readership of its website. Recent analytics show that over 330,000 users visited the website in the last 7 days alone.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced yesterday that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd. (“Shenzhen Yunma”), with LifeTech Scientific Co., Ltd. to commercialize Sorrento’s proprietary water soluble cannabidiol (CBD) formulation technologies for consumer and pharmaceutical applications in Asia (excluding Japan). In addition, Shenzhen Yunma’s subsidiary, Yunnan Masheng Health Science Co., Ltd. (“Yunnan Masheng”), has obtained a Yunnan industrial hemp plantation permit, as well as governmental pre-approval to establish an industrialized processing, CBD extraction and isolation operation in Kunming (Yunnan Province, China).

Sorrento holds 40% of the equity in the Shenzhen Yunma joint venture and LifeTech holds the remaining 60% of the equity. Sorrento has contributed the exclusive license to Sorrento’s water-soluble CBD technology for the Asian territory to Shenzhen Yunma. With the hemp and CBD supplies from Yunnan Masheng secured, Shenzhen Yunma will build manufacturing capacity to potentially deliver hundreds of metric tons of CBD annually to the global markets.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated twenty five, Inc. by the company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$VVCIF Reports Results of 2019 AGM

NAPANEE, ON, June 5, 2019 – VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company“), a leading provider of premium cannabis products and services for the medical and adult-use markets and licensed producer of cannabis under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited and ABcann Medicinals Inc., and its medical cannabis clinic network operated by Harvest Medicine Inc., today announced the results of its annual general and special meeting of shareholders held on June 4, 2019 (the “Meeting“).

The Company put forward the following resolutions to be voted on by shareholders at the Meeting, all of which were approved: (i) to re-appoint MNP LLP as auditor of the Company for the 2019 fiscal year; (ii) fixing the number of directors of the Company at six; (iii) the election of directors; and (iv) the ratification of the Company’s 2017 Stock Option Plan.

A total of 122,552,741 of the 294,800,314 common shares of the Company that were outstanding as at the record date were voted at the Meeting, representing 41.6% of such shares.

Each of the directors elected at the Meeting, being Paul Lucas, Barry Fishman, John Easson, Richard Fitzgerald, Daniel Laflamme and Daryl Kramp, will hold office until the next annual meeting of the Company or until their earlier resignation or removal. Aaron Keay did not stand for re-election at the Meeting and ceased to be a director of the Company effective June 4, 2019.

Following the Meeting, the Board determined to grant an aggregate of 575,000 stock options to certain directors and employees of the Company, each of which is exercisable into one common share of the Company at an exercise price of $0.64 share, being the closing price on June 4, 2019, until June 4, 2024. Of these, an aggregate of 475,000 options were granted to independent directors of the Company in partial satisfaction of their annual director fees, and 100,000 options were granted to an employee. The options granted will vest in stages in accordance with their respective terms. The shares issuable on exercise of the stock options will be subject to a TSX Venture Exchange hold period of four months and one day from the date of grant of the options.

About VIVO Cannabis™

VIVO, based in Napanee, Ontario, is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology at its Canna Farms facility in Hope, B.C., and at its Vanluven facility in Napanee, Ontario. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical™, Fireside™, Canna Farms™ and Lumina™. The Company is significantly expanding its production capacity and distribution channels; growing its domestic medical cannabis platform, including Harvest Medicine, its patient-centric, highly scalable network of specialty medical cannabis clinics and services; promoting production and cultivation innovation and pursuing partnership and product development opportunities; and actively focusing on growth in select international markets, including Germany and Australia. VIVO has a healthy balance sheet and is well-positioned to accelerate its growth in Canada and internationally. For more information visit: www.vivocannabis.com

ON BEHALF OF THE BOARD OF DIRECTORS

Barry Fishman
CEO and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

$INMB to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference

$VVCIF OTC Markets Group Launches OTCQX Cannabis Index

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index (.OTCQXMJ), a new performance benchmark for cannabis companies trading on the OTCQX Best Market.

The OTCQX Cannabis Index is designed to highlight for investors the diversity of high-quality Cannabis companies that meet the financial, disclosure and corporate governance standards required to trade on the OTCQX Market. Currently, there are over 450 securities from 27 countries traded on OTCQX. Eligible securities for the OTCQX Cannabis Index must be traded on OTCQX, be identified as having operations in the Cannabis space, and meet a minimum liquidity screen.

“The exponential growth in publicly-traded cannabis securities underscores the willingness of these companies to provide efficient trading and enhanced disclosure for investors,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “As an ATS, OTC Markets Group benefits from a unique business model that allows us to disrupt the exchange model and be nimble in our approach to develop standards that scale to emerging sectors.  The OTCQX Cannabis Index provides another tool for the investing public to better identify, measure and track the performance of this global industry as it progresses over time.”

As of May 31, 2019, roughly 56 cannabis-related securities trade on the OTC Markets Group’s premium OTCQX Market.  Thirty of these securities comprise the OTCQX Cannabis Index and account for approximately 25.28% of total year-to-date dollar volume in OTCQX securities.

Current OTCQX Cannabis Index Constituents:

The base date of the OTCQX Cannabis Index is April 1, 2019, and the base index level is 1,000.  The index divisor is adjusted on an ongoing basis to maintain the continuity of the index return through time.  The index is rebalanced on a quarterly basis during the months of March, June, September and December.

Index data is priced in real-time and is available on the OTC Markets Group website, www.otcmarkets.com, and via major financial data services and websites such as Bloomberg, Reuters and FT.com.

Investors cannot invest directly in the OTCQX Cannabis Index.

OTC Markets Group Inc. provides no advice, recommendation or endorsement with respect to any company or securities.  Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

To learn more about the OTCQX Cannabis Index, please visit https://www.otcmarkets.com/market-activity/indices.

OTC Markets Group’s Market Data provides mission-critical quote and trade data, as well as company and security information on OTCQX, OTCQB and Pink securities to the trading, investment, legal and regulatory communities.  The Company’s data products include real-time data, end-of-day data, historical quote data, company financial data, security master data, corporate reference data and compliance data.  OTC Markets Group also provides data through leading market data redistributors.  For more about OTC Markets Group’s market data products, including connectivity information, visit https://www.otcmarkets.com/market-data/overview.

To contact OTC Markets Market Data, call +1 (212) 220-2166 or e-mail marketdata@otcmarkets.com.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed 

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

$LXRP Announces new DehydraTECH Innovation, Files New Patents

New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.

Kelowna, British Columbia / June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.

BACKGROUND

On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.

In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).

Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.

TEST RESULTS

In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.

On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).

Click Image To View Full Size

• Enhanced DehydraTECH delivered roughly twice as much CBD to animal blood at all measured time points in the study from the 15-minute mark onwards, compared to traditional DehydraTECH; and during the same time points from 717% to 1098% more CBD than the generic industry MCT coconut oil formulations.Enhanced DehydraTECH delivered more CBD to blood in just 12 minutes than the MCT coconut-oil formulation was able to achieve at any point during the 1-hour test duration.

  Enhanced DehydraTECH is even faster acting, reaching a maximum blood concentration level (“tmax”) in just 45 minutes compared to traditional DehydraTECH at 50 minutes and the MCT coconut oil formulation at 57 minutes.

  Enhanced DehydraTECH delivered an astonishing 1,937% more CBD into animal brain tissue after 8 hours compared to generic industry MCT coconut oil formulations; and 487% more than traditional DehydraTECH.

Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.

CONCLUSION

DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.

Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.

With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.

The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250)765-6424 Ext 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBDTM, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

$TCAN Building Out Statewide Distribution and Branding Network

• TransCanna recently executed an LOI to acquire premier indoor cultivator Lyfted Farms
• Lyfted Farms also offers an SAAS (software-as-a-service) platform for cannabis
• TransCanna released a video tour of its 196,000 sq. ft facility in Modesto, California

With its proposed acquisition of Lyfted Farms Inc. of Modesto, California, TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) is showing that its search for synergies continues. The company, based in Vancouver, Canada, announced the execution of a non-binding letter of intent dated May 17, 2019, to acquire the business and assets of Lyfted (http://nnw.fm/rOf1I). The acquisition, when competed, will follow a raft of others as TransCanna continues to pursue its add-on strategy of building a branding and distribution network in California, America’s largest cannabis market. In other news, the company has made available to investors an eight-minute video, in which its CEO, Jim Pakulis, describes the features and benefits of the company’s recently acquired 196,000-square-foot cannabis facility (http://nnw.fm/HxpH5).

The acquisition of Lyfted Farms would give TransCanna a finger in many pies. Lyfted Farms holds licenses from the state of California for nursery cultivation, commercial cultivation and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://nnw.fm/TCAN

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$INMB to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference

LA JOLLA, Calif., June 04, 2019  — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that CJ Barnum, Ph.D., Director of Neuroscience, will be presenting a poster and giving a scientific talk on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019.

The poster presentation and talk, titled “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (AD) patients”, will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease.

“XPro1595 has been represented at the TNF Conference for more than a decade. I am often told that the support and feedback provided by TNF experts at this conference has gone a long way in shaping the enormous dataset that we enjoy with XPro1595. I am very excited to share how these efforts have paid off and that we are days away from enrolling the first patient in our Alzheimer’s disease trial,” says Dr. CJ Barnum.

The TNF Conference brings industry and academics together to share ideas and research on tumor necrosis factor (TNF), the target of XPro1595.

About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit June www.inmunebio.com.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
Antenna Group
Sharon Golubchik
(201) 465-8008
INmuneBio@AntennaGroup.com

Investor Contact: 
KCSA Strategic Communications
Valter Pinto / Scott Eckstein
PH: (212) 896-1254 / (212) 896-1210
INmune@KCSA.com

$GGBXF Expands MSO Presence Through Agreement to Acquire Spring Oaks

$TGODF Cannabis Approval Ratings are Only Increasing in North America Again

Palm Beach, FL – June  4, 2019 –  An estimated 64 million Americans have tried some form of CBD in the last 24 months, with nearly one out of seven using the compound every day, according to a Consumer Reports survey.  In addition, according to The General Social Survey conducted by NORC at the University of Chicago, 61% of those surveyed support legalization. That’s up from 57% in 2016.  A Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016. A Pew survey found that 62% of Americans want to see cannabis legalization in the country, as compared to just 57% in 2015.  That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF),  Canopy Growth Corporation (NYSE:CGC)(TSX:WEED), Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB), Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTC:CWBHF), and The Green Organic Dutchman Holdings Ltd. (TSX:TGOD)(OTC:TGODF).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that its wholly owned subsidiary Urban Juve is accessing the multi-billion-dollar wellness market by launching international e-commerce sales.  In addition to all major credit cards, the urbanjuve.com site will be equipped to receive payments through PayPal, WeChat, and Alipay.  Urbanjuve.com represents a new paradigm in scalable e-commerce websites—and was purpose-built with rapid expansion in mind. Agile and flexible, the system supports seamless procurement, payment processing integration and inventory management, offering considerable visibility into data and performance. “The website was designed with the ultimate goal of  global expansion, so Yield Growth was able to launch and test capabilities in Canada and then expand into new territories more quickly than an average e-commerce company,” says Penny Green, CEO of Yield Growth. Because we’ve been thinking about growth from the beginning, we will be able to establish our brand in new, international markets with a first-mover advantage.”  In order to support international sales, Yield Growth is working with an established network of third-party suppliers to streamline manufacturing, warehousing, and fulfillment.   For more information on BOSS, please visit:  https://yieldgrowth.com/

Other cannabis-related developments from around the markets include:

Canopy Growth Corp. (NYSE:CGC)(TSX:WEED) just announced the next phase in its partnership with Parent Action on Drugs and Canadian Students for Sensible Drug Policy which will see PAD launch two new digital tools to help youth along with their parents, adult caregivers, and influencers, on how to make responsible decisions about cannabis use. PAD employed the technical expertise of Massively, a leader in artificial intelligence, to develop a fun and interactive chatbot designed to engage, educate and encourage conversation between parents and their kids about cannabis. This tool helps parents structure conversations with their pre-teens about cannabis to inform and prevent early use, associated with a number of negative short and long-term outcomes. By having an informed, open dialogue about cannabis, parents can protect their children while creating a culture of knowledge and resiliency.

Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB) and the UFC, the world’s premier mixed martial arts organization just announced a multi-year, multi-million-dollar, global partnership that is expected to significantly advance further clinical research on the relationship between 100% hemp derived Cannabidiol (CBD) products and athlete wellness and recovery, with a view to accelerating CBD product development and education.  The research will be conducted at the UFC’s Performance Institute in Las Vegas, Nevada, in collaboration with UFC’s sports performance team, as well as with athletes who choose to participate in the studies. Clinical studies will focus on pain management, inflammation, injury/exercise recovery, and mental well-being. Aurora’s research will be led by Dr. Jason Dyck, Professor at the University of Alberta and a Canada Research Chair in Molecular Medicine. He also serves as an independent director on the board of Aurora Cannabis, where he provides valuable oversight for the Company’s scientific efforts.

Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTCQX:CWBHF) just announced today that the Underwriters of its previously-announced underwritten public offering of 7,000,000 common shares of the Company sold by certain current shareholders at a price of C$20.00 per share have exercised in full their option to purchase an additional 1,050,000 common shares from the Selling Shareholders at the Offering Price. The gross proceeds to the Selling Shareholders under the exercise of this over-allotment will be C$21,000,000, and together with the gross proceeds from the initial closing on May 15, 2019 of C$140,000,000, the aggregate gross proceeds of the offering will be $161,000,000.

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD)(OTCQX:TGODF) just obtained approval from Health Canada, under the Cannabis Regulations, to expand operations into its new state-of-the-art building located in Hamilton, Ontario. The 20,000 square feet indoor facility is going to be used for cannabis cultivation; planting will start in the coming weeks.  “This is yet another important milestone for our team as we continue to ramp up production with a focus on executional excellence,” commented Brian Athaide, CEO of TGOD. “We have pioneered the concept of sustainably growing all-natural, certified organic cannabis at scale. The product we are able to offer Canadians is clean, pesticide-free and undeniably premium.” The newly built facility is the second of three buildings at TGOD’s Hamilton site, which will have a total size of 166,000 square feet when all are completed later this summer, and an annual production capacity of 17,500 kgs.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated forty six hundred dollars for news coverage of the current press release issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$OGI is “One to Watch”

• H1 2019 results reflect excellent operational execution: lowest cost of cultivation per gram among publicly reporting Canadian LPs, industry-leading adjusted gross margin and adjusted EBITDA (positive adjusted EBITDA for 3rd consecutive quarter in Q2 2019)
• On track to increase target production capacity to 113,000 kg/year by the end of 2019
• Well-positioned for Canada’s new edibles and derivative legalization expected in October 2019 with expanding production capacity, R&D and various strategic partnerships
• Invested in biosynthesis to produce cannabinoids without growing the plant at a fraction of cultivation costs
• Focused on developing further international partnerships, prioritizing the CBD market

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint.

The Company has distribution arrangements in all 10 provinces. Organigram delivers industry-leading yields and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://nnw.fm/OGRMF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com